Brokers Set Expectations for BMRN FY2026 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biotechnology company will earn $4.29 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $90.00 price target on the stock. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share.

A number of other research analysts have also weighed in on BMRN. Scotiabank lifted their price target on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a research note on Thursday, February 20th. Bank of America raised their price objective on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Wall Street Zen raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Piper Sandler increased their target price on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a report on Thursday, February 20th. Finally, Wedbush reissued an "outperform" rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $93.45.

BioMarin Pharmaceutical Stock Down 1.9%

Shares of BMRN traded down $1.06 on Tuesday, hitting $56.22. The company's stock had a trading volume of 1,623,311 shares, compared to its average volume of 1,831,883. The firm's fifty day moving average price is $59.10 and its 200-day moving average price is $64.00. BioMarin Pharmaceutical has a fifty-two week low of $52.93 and a fifty-two week high of $94.85. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $10.78 billion, a price-to-earnings ratio of 25.55, a P/E/G ratio of 0.61 and a beta of 0.19.

Insiders Place Their Bets

In other news, CAO Erin Burkhart sold 1,786 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $59.31, for a total value of $105,927.66. Following the completion of the sale, the chief accounting officer now owns 14,173 shares of the company's stock, valued at approximately $840,600.63. This represents a 11.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 3,354 shares of company stock valued at $216,269 in the last 90 days. 0.85% of the stock is currently owned by insiders.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of BMRN. Rise Advisors LLC acquired a new stake in shares of BioMarin Pharmaceutical during the 1st quarter worth about $30,000. Farther Finance Advisors LLC lifted its position in BioMarin Pharmaceutical by 95.9% during the first quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 211 shares during the period. LRI Investments LLC boosted its position in shares of BioMarin Pharmaceutical by 856.9% during the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 437 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its stake in shares of BioMarin Pharmaceutical by 71.2% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 218 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in BioMarin Pharmaceutical during the fourth quarter worth about $36,000. Institutional investors own 98.71% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.